Access Pharmaceuticals Announces Presentation Of ProLindac(TM) Data At International Conference

DALLAS, Feb. 21 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. announced today that recent clinical data for ProLindac(TM), its novel DACH platinum polymer prodrug, is being presented at the International Symposium on Polymer Therapeutics at the Freie Universitat Berlin, in Germany. Following encouraging Phase I clinical results, ProLindac(TM) is currently in two Phase II studies.

The symposium presentation, given by David P. Nowotnik, Ph.D., Access' Senior Vice President, Research and Development, is entitled "Results of preclinical and clinical studies on ProLindac(TM) (AP5346), a DACH-platinum HPMA polymer prodrug", and provides an overview of the development of this product to-date. ProLindac(TM) has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. The Company believes that ProLindac(TM)'s unique molecular design potentially could eliminate some of the toxic neurological side effects seen in currently marketed DACH platinums. The Company is currently enrolling patients in two Phase II clinical trials, one in ovarian cancer and the other in head and neck cancer, and plans to initiate one or more additional Phase II trials, including one in colorectal cancer in 2007.

"On the behalf of my colleagues at Access, I am pleased to be discussing preclinical and clinical studies on ProLindac(TM), which has the potential to be an effective new polymer-based therapeutic agent for cancer patients. Access' presence at this international symposium, focused specifically on polymer therapeutics, yields great recognition for our lead drug candidate ProLindac(TM), especially among the best and brightest minds within our industry," commented Dr. Nowotnik.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on developing and commercializing propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the management of patients with mucositis for which marketing allowance has been granted by the FDA. The Company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the value of our products in the market, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission.

CONTACT: Stephen B. Thompson, Vice President, Chief Financial Officer ofAccess Pharmaceuticals, Inc., +1-214-905-5100; or investor relations,Donald C. Weinberger, or media, Alisa Steinberg, both of Wolfe AxelrodWeinberger LLC, +1-212-370-4500, for Access Pharmaceuticals, Inc.

Web site: http://www.accesspharma.com/